Imagine a world where we could outsmart cancer by targeting its very fuel source. This is the bold vision presented at the CTOS 2025 Annual Meeting by Dr. Kathryn Lemberg, who unveiled groundbreaking research on harnessing cancer metabolism to combat soft tissue sarcomas (STS). But here's where it gets controversial: can we truly exploit the metabolic weaknesses of these aggressive tumors to develop effective treatments? Dr. Lemberg's presentation focused on two particularly challenging STS subtypes: rhabdomyosarcoma (RMS), the most common STS in children, and malignant peripheral nerve sheath tumor (MPNST), a leading cause of death in young patients with neurofibromatosis type 1. These cancers are notoriously difficult to treat, with limited options and poor outcomes after relapse. And this is the part most people miss: the key might lie in understanding how these tumors utilize nutrients like glutamine and synthesize essential molecules like nucleotides.
The Metabolic Achilles' Heel of Sarcoma
Cancer's ability to manipulate its metabolism for rapid growth and survival is well-known. In STS, this metabolic flexibility becomes a double-edged sword, driving disease progression and resistance to treatment. Thanks to advancements in technologies like mass spectrometry and metabolic imaging, researchers can now map these intricate processes in unprecedented detail. However, translating these findings into effective therapies remains a significant hurdle due to limited model systems, small patient populations, and the complexity of metabolic pathways.
Rhabdomyosarcoma: Cracking the Code of Metabolic Dependency
RMS, affecting approximately 350 children annually in the U.S., originates from muscle cells and has two main subtypes. While standard treatment involves surgery, radiation, and chemotherapy, high-risk cases often have poor outcomes. Research is now focusing on exploiting metabolic vulnerabilities. For instance, fusion-positive RMS cells heavily rely on de novo pyrimidine synthesis, a pathway crucial for DNA and RNA production. In fusion-negative RMS, inhibiting glutaminase, an enzyme involved in glutamine metabolism, sensitizes tumors to radiotherapy, leading to improved tumor control in animal models. Additionally, targeting the NAD⁺ biosynthesis pathway with NAMPT inhibitors has shown promising results in preclinical studies, depleting cellular energy and inducing tumor regression. These findings suggest that disrupting metabolic circuits, rather than solely targeting traditional signaling pathways, could be a game-changer in STS treatment.
MPNST: Metabolism as a Driver of Aggressiveness
MPNSTs present a unique challenge due to their association with NF1 and their aggressive nature. Current treatment options are limited, with surgery being the only curative approach. However, recent research has identified specific metabolic vulnerabilities in MPNSTs. For example, inhibiting glutamine amidotransferase, an enzyme involved in nitrogen metabolism, significantly impairs tumor growth by reducing nucleotide synthesis. Even more remarkably, combining this inhibitor with a purine salvage pathway inhibitor completely halted tumor growth in preclinical models, highlighting the potential of synthetic lethality strategies. Interestingly, resistance to MEK inhibitors, a common targeted therapy, might actually sensitize MPNST cells to glutamine-targeted therapy, revealing a complex interplay between metabolic reprogramming and oncogenic signaling.
The Road Ahead: From Lab to Patient
The future of metabolic therapy in STS hinges on translating these laboratory discoveries into patient-ready interventions. Key research priorities include understanding how specific tumor mutations influence metabolic sensitivity, expanding studies to other RAS-driven sarcomas, and investigating the role of glutamine-targeting drugs in modulating the immune microenvironment. A recurring theme throughout Dr. Lemberg's presentation was the need for combination therapies. Tumors are adept at adapting to single-target approaches, making combination strategies that pair metabolic inhibition with radiotherapy, targeted therapy, or immune modulation the most promising path forward.
A New Paradigm in Sarcoma Treatment
The renewed focus on cancer metabolism reflects the significant progress made in sarcoma biology. From advanced metabolomic profiling to genetically engineered models, researchers are uncovering hidden biochemical dependencies that could finally open new therapeutic avenues for patients with these rare and devastating tumors. Success will depend on strong collaboration between basic scientists, clinicians, industry partners, and the invaluable participation of patients and families. Dr. Lemberg's work and her collaborators at Johns Hopkins and beyond represent a significant step towards a new paradigm where metabolism becomes the Achilles' heel of soft tissue sarcomas.
This research raises important questions: Can we truly outsmart cancer by targeting its metabolic vulnerabilities? What are the potential side effects of these novel therapies? And how can we ensure equitable access to these potentially life-saving treatments? We invite you to share your thoughts and join the discussion in the comments below. For more information, visit https://ctos2025.eventscribe.net/agenda.asp?pfp=days&day=11/12/2025&theday=Wednesday&h=Wednesday%20November%2012&BCFO=P|G.
